Data-driven, proprietary approach powers a robust omnichannel
platform to help pharmaceutical companies innovate their rare disease
marketing efforts
BOSTON–(BUSINESS WIRE)–Cambridge
BioMarketing, an Ashfield company, part of UDG Healthcare plc and
the world’s leading rare disease agency, today announced the launch of
RareID, the agency’s new, proprietary approach to identifying rare
disease market solutions.
RareID uses proven, predictive model-matching applications and
journey-mapping techniques customized for the rare disease market,
enabling clients to confidently understand how to best reach their
customers. By combining client algorithms with Cambridge BioMarketing’s
rare disease knowledge base, the solution helps develop the most
effective market-shaping strategies, messaging, and
patient-find-and-activate initiatives to help clients reach patients
efficiently and effectively.
“Each rare disease patient and their respective community is even more
dynamic and rare than their diagnosis,” said Marissa McNally, head of
Strategy, Cambridge BioMarketing. “RareID enables us to help our clients
understand those patients at deeper levels and deliver their solutions
directly to those who need them most.”
The development of RareID stems from the agency’s enduring commitment to
service, strategy, and a deep understanding of rare medicine’s
intersection with omnichannel solutions. Four tenets of the approach
include:
-
Find both diagnosed and undiagnosed patients—and the HCPs
likely to treat them—so that they can get the answers, medicine, and
support they deserve quicker than ever before. -
Develop markets and launch meaningful brands—for both novel and
crowded treatment categories—that accelerate time to diagnosis,
empower patients to demand more from their HCPs, and give HCPs a
concrete way to offer hope to some of their toughest cases. -
Activate rare communities to drive awareness, diagnosis, and
urgency, and spark patients and HCPs to champion new treatment
paradigms that align with their wants and needs. -
Nurture relationships between patients, HCPs, industry, and
advocacy organizations to foster a level of empathy and understanding
that results in optimal support for rare communities.
RareID marks the latest chapter in the agency’s evolution
including a new,
interactive website, as well as an updated color palate, evolving
from Cambridge BioMarketing’s original black and red branding to navy
and a brighter red. The brand updates reflect the agency’s roots in the
rare experience and represent its sophistication and deep knowledge in
rare disease marketing.
About Cambridge BioMarketing
Founded in 2001, Cambridge BioMarketing is a U.S.-based communications
agency specializing in rare orphan diseases with over 100 employees.
Headquartered in Boston, MA with offices in Oakland, CA, Cambridge
BioMarketing is an industry leader in orphan drug launches, advising
pharmaceutical companies with an integrated focus on both traditional
healthcare professional (HCP) programs and direct-to-patient work. In
partnering with predominantly pharmaceutical and biotech customers, the
agency’s goal is to bring physicians, specialists, and patient
communities together on behalf of clients to transform human health in
the face of devastating, under-appreciated disease states. Cambridge
BioMarketing’s primary service offerings include: launch readiness
support; digital strategy; market analytics; integrated marketing;
patient identification and acquisition; medical affairs support; line
extensions and patient retention and adherence programs.
For more information, please go to: http://cambridgebmg.com/
About Ashfield:
Ashfield is part of UDG Healthcare plc, a global leader in
commercialization services for the healthcare industry. We partner with
our clients across Advisory, Healthcare Communications, Commercial,
Patient Solutions and Medical Affairs to build creative, scalable and
tailored health solutions that are executed flawlessly, to deliver
positive outcomes for patients and add value to your business. With
7,000 employees, the company operates in 25 countries, delivering
services in more than 50 countries across Europe, North America, South
America and Asia. It works with more than 250 businesses, including all
of the world’s top 25 pharmaceutical companies.
Its mission is to partner with its clients, helping to improve lives by
ensuring healthcare professionals and patients get the medicines,
knowledge and support they need.
Ashfield provides contract sales teams, customer service reps, medical
science liaison officers, remote detailing, nurse educators, medical
information, healthcare communications, market access, market research,
training, live and virtual events, digital, creative, pharmacovigilance,
audit and advisory services.
For more information, go to www.ashfieldhealthcare.com.
Contacts
PAN Communications, for Cambridge BioMarketing
Taylor VerMeer,
617-502-4300
cbm@pancomm.com